An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 [interleukin-4-(38-37)-PE38KDEL] in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2013
At a glance
- Drugs MDNA 55 (Primary)
- Indications Breast cancer; Non-small cell lung cancer; Renal cancer
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
- 31 Aug 2018 Biomarkers information updated
- 19 Sep 2005 New trial record.
- 03 Jun 2003 Interim results reported at ASCO 2003.